Identification of small molecules as potential inhibitors of interleukin 6: a multi-computational investigation
Tóm tắt
IL(interleukin)-6 is a multifunctional cytokine crucial for immunological, hematopoiesis, inflammation, and bone metabolism. Strikingly, IL-6 has been shown to significantly contribute to the initiation of cytokine storm—an acute systemic inflammatory syndrome in Covid-19 patients. Recent study has showed that blocking the IL-6 signaling pathway with an anti-IL-6 receptor monoclonal antibody (mAb) can reduce the severity of COVID-19 symptoms and enhance patient survival. However, the mAb has several drawbacks, such as high cost, potential immunogenicity, and invasive administration due to the large-molecule protein product. Instead, these issues could be mitigated using small molecule IL-6 inhibitors, but none are currently available. This study aimed to discover IL-6 inhibitors based on the PPI with a novel camelid Fab fragment, namely 68F2, in a crystal protein complex structure (PDB ID: 4ZS7). The pharmacophore models and molecular docking were used to screen compounds from DrugBank databases. The oral bioavailability of the top 24 ligands from the screening was predicted by the SwissAMDE tool. Subsequently, the selected molecules from docking and MD simulation illustrated a promising binding affinity in the formation of stable complexes at the active binding pocket of IL-6. Binding energies using the MM-PBSA technique were applied to the top 4 hit compounds. The result indicated that DB08402 and DB12903 could form strong interactions and build stable protein–ligand complexes with IL-6. These potential compounds may serve as a basis for further developing small molecule IL-6 inhibitors in the future.
Tài liệu tham khảo
Jiang Y, Rubin L, Peng T, Liu L, Xing X, Lazarovici P, Zheng W (2022) Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. Int J Biol Sci 18:459–472. https://doi.org/10.7150/ijbs.59272
Ogata A, Kato Y, Higa S, Yoshizaki K (2019) IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod Rheumatol 29:258–267. https://doi.org/10.1080/14397595.2018.1546357
Gorham J, Moreau A, Corazza F, Peluso L, Ponthieux F, Talamonti M, Izzi A, Nagant C, Djangang NN, Garufi A, Creteur J, Taccone FS (2020) Interleukine-6 in critically ill COVID-19 patients: a retrospective analysis. PLoS ONE 15:e0244628. https://doi.org/10.1371/journal.pone.0244628
Abdin SM, Elgendy SM, Alyammahi SK, Alhamad DW, Omar HA (2020) Tackling the cytokine storm in COVID-19, challenges and hopes. Life Sci 257:118054. https://doi.org/10.1016/j.lfs.2020.118054
Coomes EA, Haghbayan H (2020) Interleukin-6 in Covid-19: a systematic review and meta-analysis. Rev Med Virol 30:1–9. https://doi.org/10.1002/rmv.2141
Kishimoto T (2010) IL-6: from its discovery to clinical applications. Int Immunol 22:347–352. https://doi.org/10.1093/intimm/dxq030
Scheller J, Chalaris A, Schmidt-Arras D, Rose-Jone S (2011) The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813:878–888. https://doi.org/10.1016/j.bbamcr.2011.01.034
Somers W, Stahl M, Seehra JS (1997) 1.9 Å crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. Embo J 16:989–997. https://doi.org/10.1093/emboj/16.5.989
Blanchetot C, Jonge ND, Desmyter A, Ongenae N, Hofman E, Klarenbeek A, Sadi A, Hultberg A, Kretz-Rommel A, Spinelli S, Loris R, Cambillau C, Haard HD (2016) Structural mimicry of receptor interaction by antagonistic interleukin-6 (IL-6) antibodies. J Biol Chem 291:13846–13854. https://doi.org/10.1074/jbc.M115.695528
Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334:297–314. https://doi.org/10.1042/bj3340297
Paonessa G, Graziani R, Serio AD, Savino R, Ciapponi L, Lahm A, Salvati AL, Toniatti C, Ciliberto G (1995) Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling. Embo J 14:1942–1951. https://doi.org/10.1002/j.1460-2075.1995.tb07186.x
Boulanger MJ, Chow DC, Brevnova EE, Garcia KC (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 300:2101–2104. https://doi.org/10.1126/science.1083901
Chalaris A, Schmidt-Arras D, Yamamoto K, Rose-John S (2012) Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Dig Dis 30:492–499. https://doi.org/10.1159/000341698
Garbers C, Heink S, Korn T, Rose-John S (2018) Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov 17:395–412. https://doi.org/10.1038/nrd.2018.45
Atal S, Fatima Z (2020) IL-6 Inhibitors in the treatment of serious COVID-19: a promising therapy? Pharmaceut Med 34:223–231. https://doi.org/10.1007/s40290-020-00342-z
Kishimoto T (2021) IL-6: from arthritis to CAR-T-cell therapy and COVID-19. Int Immunol 33:515–519. https://doi.org/10.1093/intimm/dxab011
Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA (2020) The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. J Allergy Clin Immunol 146:P518-534. https://doi.org/10.1016/j.jaci.2020.07.001
Mai TT, Nguyen PG, Le MT, Tran TD, Huynh PNH, Trinh DT, Nguyen QT, Thai KM (2022) Discovery of small molecular inhibitors for interleukin-33/ST2 protein-protein interaction: a virtual screening, molecular dynamics simulations and binding free energy calculations. Mol Divers 26:2659–2678. https://doi.org/10.1007/s11030-021-10359-4
Meng XY, Zhang HX, Mezei M, Cui M (2012) Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 7:146–157. https://doi.org/10.2174/157340911795677602
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46:D1074-1082. https://doi.org/10.1093/nar/gkx1037
Molecular Operating Environment (MOE) (2015) Version 2015.10. Chemical Computing Group Inc., Montreal
Kalai M, Montero-Julian FA, Grötzinger J, Fontaine V, Vandenbussche P, Deschuyteneer R, Wollmer A, Brailly H, Content J (1997) Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction. Blood 89:1319–1333
The Protein Data Bank. https://www.rcsb.org/structure/4ZS7. Accessed 20 June 2021
LeadIT. Version 2.1.8. https://www.biosolveit.de/LeadIT. Accessed 15 Sep 2021
Ngo TD, Tran TD, Le MT, Thai KM (2016) Computational predictive models for P-glycoprotein inhibition of in-house chalcone derivatives and drug-bank compounds. Mol Divers 20:945–961. https://doi.org/10.1007/s11030-016-9688-5
Sekhar PN (2021) Computational prediction of hERG blockers using homology modelling, molecular docking and QuaSAR studies. Results Chem 3:100101. https://doi.org/10.1016/j.rechem.2021.100101
Delaney JS (2004) ESOL: estimating aqueous solubility directly from molecular structure. J Chem Inf Comput Sci 44:1000–1005. https://doi.org/10.1021/ci034243x
Daina A, Zoete V (2016) A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 11:1117–1121. https://doi.org/10.1002/cmdc.201600182
Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717. https://doi.org/10.1038/srep42717
Tran TS, Le MT, Tran TD, Tran TH, Thai KM (2020) Design of curcumin and flavonoid derivatives with acetylcholinesterase and beta-secretase inhibitory activities using in silico approaches. Molecules 25:3644. https://doi.org/10.3390/molecules25163644
Lindahl E, Abraham MJ, Hess B, Spoel Dvd (2021) GROMACS 2021.02 Documentation (Release 2021.02). Zenodo. https://doi.org/10.5281/zenodo.4457591
Mackerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FTK, Matto C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiórkiewicz-Kuczera J, Yin D, Karplus M (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102:3586–3616. https://doi.org/10.1021/jp973084f
Zoete V, Cuendet MA, Grosdidier A, Michielin O (2011) SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem 32:2359–2368. https://doi.org/10.1002/jcc.21816
Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR (2012) Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminform 4:17. https://doi.org/10.1186/1758-2946-4-17
Bepari AK, Reza HM (2021) Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation. PeerJ 9:e11261. https://doi.org/10.7717/peerj.11261
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33–38. https://doi.org/10.1016/0263-7855(96)00018-5
Nguyen PT, Yu H, Keller PA (2014) Discovery of in silico hits targeting the nsP3 macro domain of chikungunya virus. J Mol Model 20:2216. https://doi.org/10.1007/s00894-014-2216-6
Kumari R, Kumar R, Lynn A (2014) g_mmpbsa–a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model 54:1951–1962. https://doi.org/10.1021/ci500020m
Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang JZH, Hou T (2019) End-point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design. Chem Rev 119:9478–9508. https://doi.org/10.1021/acs.chemrev.9b00055
Homeyer N, Gohlke H (2012) Free energy calculations by the molecular mechanics Poisson-Boltzmann surface area method. Mol Inform 31:114–122. https://doi.org/10.1002/minf.201100135
Genheden S, Ryde U (2015) The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10:449–461. https://doi.org/10.1517/17460441.2015.1032936
Chéron N, Shakhnovich EI (2017) Effect of sampling on BACE-1 ligands binding free energy predictions via MM-PBSA calculations. J Comput Chem 38:1941–1951. https://doi.org/10.1002/jcc.24839
Lipinski CA (2004) Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 1:337–341. https://doi.org/10.1016/j.ddtec.2004.11.007
Ghose AK, Viswanadhan VN, Wendoloski JJ (1999) A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1:55–68. https://doi.org/10.1021/cc9800071
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615–2623. https://doi.org/10.1021/jm020017n
Egan WJ, Merz KM, Baldwin JJ (2000) Prediction of drug absorption using multivariate statistics. J Med Chem 43:3867–3877. https://doi.org/10.1021/jm000292e
Muegge I, Heald SL, Brittelli D (2001) Simple selection criteria for drug-like chemical matter. J Med Chem 44:1841–1846. https://doi.org/10.1021/jm015507e
Ali SA, Hassan MI, Islam A, Ahmad F (2014) A review of methods available to estimate solvent-accessible surface areas of soluble proteins in the folded and unfolded states. Curr Protein Pept Sci 15:456–476. https://doi.org/10.2174/1389203715666140327114232
Lobanov MY, Bogatyreva NS, Galzitskaya OV (2008) Radius of gyration as an indicator of protein structure compactness. Mol Biol 42:623–628. https://doi.org/10.1134/S0026893308040195
Oyewusi HA, Huyop F, Wahab RA (2022) Molecular docking and molecular dynamics simulation of Bacillus thuringiensis dehalogenase against haloacids, haloacetates and chlorpyrifos. J Biomol Struct Dyn 40:1979–1994. https://doi.org/10.1080/07391102.2020.1835727
Lauria A, Tutone M, Ippolito M, Pantano L, Almerico AM (2010) Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules. Curr Med Chem 17:3142–3154. https://doi.org/10.2174/092986710792232021
Tran TT, Tran QH, Nguyen QT, Le MT, Trinh DT, Thai KM (2022) Identification of potential interleukin-8 inhibitors acting on the interactive site between chemokine and CXCR2 receptor: a computational approach. PLoS ONE 17:e0264385. https://doi.org/10.1371/journal.pone.0264385
Tran QH, Nguyen QT, Vo NQ, Mai TT, Tran TT, Tran TD, Le MT, Trinh DT, Thai KM (2022) Structure-based 3D-Pharmacophore modeling to discover novel interleukin 6 inhibitors: an in silico screening, molecular dynamics simulations and binding free energy calculations. PLoS ONE 17:e0266632. https://doi.org/10.1371/journal.pone.0266632
Thai KM, Ngo TD, Tran TD, Le MT (2013) Pharmacophore Modeling for Antitargets. Curr Top Med Chem 13:1002–1014. https://doi.org/10.2174/1568026611313090004
Mak KK, Pichika MR (2019) Artificial intelligence in drug development: present status and future prospects. Drug Discov Today 24:773–780. https://doi.org/10.1016/j.drudis.2018.11.014